Abstract
In summary, we believe that if clinical audit is accepted and prosecuted as the third clinical science, it has the potential to deliver substantial benefits to patients and health professionals.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Donabedian A. Evaluating the quality of medical care. Milbank Mem Fund Q. 1966 Jul;44(3 Suppl):166–206. [PubMed] [Google Scholar]
- Eccles M., Bradshaw C. Use of secondary prophylaxis against myocardial infarction in the north of England. BMJ. 1991 Jan 12;302(6768):91–92. doi: 10.1136/bmj.302.6768.91. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Healy M. J. Truth and consequences in medical research. Lancet. 1978 Dec 16;2(8103):1300–1301. doi: 10.1016/s0140-6736(78)92056-1. [DOI] [PubMed] [Google Scholar]
- Mueller H. S., Ayres S. M. Propranolol decreases sympathetic nervous activity reflected by plasma catecholamines during evolution of myocardial infarction in man. J Clin Invest. 1980 Feb;65(2):338–346. doi: 10.1172/JCI109677. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mugford M., Banfield P., O'Hanlon M. Effects of feedback of information on clinical practice: a review. BMJ. 1991 Aug 17;303(6799):398–402. doi: 10.1136/bmj.303.6799.398. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Schwartz D., Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis. 1967 Aug;20(8):637–648. doi: 10.1016/0021-9681(67)90041-0. [DOI] [PubMed] [Google Scholar]
- Yusuf S., Peto R., Lewis J., Collins R., Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335–371. doi: 10.1016/s0033-0620(85)80003-7. [DOI] [PubMed] [Google Scholar]